News

We’re pleased to share that Neurim Pharmaceuticals has signed an exclusive licensing and distribution agreement with KYE Pharmaceuticals Inc. to bring SLENYTO® (Extended-release melatonin) to the Canadian market. This partnership […]

Join Neurim Pharmaceuticals at the EAPS 2025 Congress in Lisbon and attend our satellite symposium, “Insomnia management in children with ASD & ADHD: An opportunity to improve developmental and behavioral […]

We are pleased to announce that Health Canada has granted marketing authorization for Slenyto®- Extended-Release Melatonin Formulation – as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder […]

October is ADHD Awareness Month. For many children with ADHD, bedtime is just the beginning of another struggle. Sleep disturbances affect not only the child, but also daily life and […]

October is ADHD Awareness Month. ADHD doesn’t end when the day does – sleep challenges play a bigger role than many realize. Watch this video to learn more:  

Neurim Pharmaceuticals is excited to attend the ESCAP 2025 Congress in Strasbourg! We cordially invite all ESACP 2025 delegates to join our Satellite Symposium on “Towards a unified approach to treatment of […]

We were excited to bring together our international partners once again for a productive Partners Meeting, centered on strategic direction, knowledge sharing, and collaboration, all in support of advancing care […]

On World Autism Awareness Day, we remain dedicated to supporting individuals on the spectrum, day and night. Together, let’s spread awareness, foster inclusion, and make a real difference. Watch this […]

We are pleased to share that Neurim Pharmaceuticals has received European Marketing Authorization for Pediatric Prolonged-Release Melatonin (Slenyto®) for the treatment of insomnia in children with Attention Deficit Hyperactivity Disorder […]